FEATURED CONTENT

• What Is ICH GCP, And How Does It Impact Clinical Planning?

  The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.

• Clinical Trial Disclosure Noncompliance: What Is Its Impact On Pharma M&As?

  Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.

• Challenges, Opportunities For Recruitment In The Digital Age

  Health literacy gaps and online misinformation hinder clinical trial recruitment. Meeting patients where they are — digitally and educationally — can improve engagement and enrollment success.

• The Healing Power Of Support Groups

  Support groups offer emotional strength and connection for patients and caregivers, helping them navigate medical challenges, treatment journeys, and the complexities of chronic conditions.

• How AI Is Reshaping Trial Design, Execution, And Disclosure

  AI has quietly embedded itself into the operational heart of clinical development, where it is accelerating decisions, reducing manual burden, and improving outcomes.

• A New Blueprint For Transforming Feasibility And Recruitment

  Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.

• Real-World Data Has Real Impact On Clinical Research

  The ultimate goal of using real-world data (RWD) in clinical research is to ensure a patient is on the right therapy and receiving the right care at the right point in their healthcare journey.

• AI Won't Replace You — But Clinical Teams Using It Might

  Join experts as they reveal how AI is being used today across feasibility, site selection, and trial strategy — and why success depends on pairing AI with high-quality, expert-backed data.

• Infographic: Every Completed Trial, Every Emerging Trend

  Explore the data behind every trial completed last year — uncovering key trends, leading sponsors, and therapeutic areas shaping the future of clinical research.

• Biotech Landscape Continues To Shift

  Global shifts are adding new layers of challenge and opportunity for the biotech sector, as companies navigate a period of unprecedented complexity.

• Expand Bandwidth With A Trusted Regulatory Writing Partner

  Find out how a mid-size biotech lacking the bandwidth, expertise, and resources to independently handle its regulatory writing requirements overcame this challenge.

• ICH E6(R3): 10 FAQ On What Changed And What It Means For Your Trials

  The ICH E6(R3) updated guidelines present 10 critical changes to make clinical trials more efficient, adaptable, and patient-centric, while upholding the standards of scientific and ethical integrity.

• Inclusive Trial Design A 'Must-Have' In Modern R&D

  Inclusivity in trial design is a crucial aspect of the R&D process, recognized for its importance to ensuring scientific validity, ethical responsibility, and public health.

• Gene Therapy Studies Rose While Financing Declined In Q2 2025

  There were three new approvals across the therapeutic landscape in the second quarter of 2025, but despite those positive signs, overall dealmaking was flat for the quarter.

• Completed Trials Climb At Faster Pace

  In 2024, the number of industry-sponsored clinical trials reaching completion accelerated significantly. Explore the trial counts and rankings, top 5 diseases for trials, and more.

• RWD, New Technologies Show Potential In Clinical Trial Recruitment

  Leveraging RWD transforms feasibility and recruitment from reactive processes into strategic drivers of clinical trial success.

• Clinical Trials Need To Take The Whole Patient Into Account

  Explore how inclusivity in clinical trials needs to encompass the whole patient, taking into account factors like race, sex, age, ethnicity, sexual orientation, and physical abilities or qualities.

• Use Case: How Consulting & Analytics Can Guide Clinical Strategy

  A large European pharmaceutical company sought to benchmark a CRO’s suggestions involving a Phase III trial for a newly acquired asset.

• 8 Tips For Producing Masterful Plain Language Summaries

  Following these tips will ensure high-quality plain language summaries (PLS) that meet EU parameters while clearly communicating clinical trial information to patients and the public.

• Sickle Cell Cure Within Reach, But At A Steep Cost

  Treatment options for sickle cell disease (SCD) and newly available gene therapies represent a potential cure. However, the latter are costly and thus remain out of reach for many SCD patients.